Regarding therapeutic viability, the ELAD trial is evaluating the effect of liraglutide, an incretin mimetic, in participants with early AD.25 This is based on preclinical data suggesting that the glucagon-like peptide-1 (GLP-1) analogue reduces Aβ oligomers and normalises synaptic plasticity. This evidence concerns the gene GCG and Alzheimer disease.